

Journal Pre-proof



Introduction of *Aedes aegypti* mosquitoes carrying *wAlbB Wolbachia* sharply decreases dengue incidence in disease hotspots

Ary A. Hoffmann, Nazni Wasi Ahmad, Wan Ming Keong, Cheong Yoon Ling, Noor Afizah Ahmad, Nick Golding, Nicholas Tierney, Jenarun Jelip, Perada Wilson Putit, Norhayati Mokhtar, Sukhvinder Singh Sandhu, Lau Sai Ming, Khadijah Khairuddin, Kamilan Denim, Norazman Mohd Rosli, Hanipah Shahar, Topek Omar, Muhammad Kamarul Ridhuan Ghazali, Nur Zatil Aqmar Mohd Zabari, Mohd Arif Abdul Karim, Mohamad Irwan Saidin, Muhammad Nizam Mohd Nasir, Tahir Aris, Steven P. Sinkins

PII: S2589-0042(24)00163-9

DOI: <https://doi.org/10.1016/j.isci.2024.108942>

Reference: ISCI 108942

To appear in: *ISCIENCE*

Received Date: 17 October 2023


Revised Date: 22 November 2023

Accepted Date: 15 January 2024

Please cite this article as: Hoffmann, A.A., Ahmad, N.W., Keong, W.M., Ling, C.Y., Ahmad, N.A., Golding, N., Tierney, N., Jelip, J., Putit, P.W., Mokhtar, N., Sandhu, S.S., Ming, L.S., Khairuddin, K., Denim, K., Rosli, N.M., Shahar, H., Omar, T., Ridhuan Ghazali, M.K., Aqmar Mohd Zabari, N.Z., Abdul Karim, M.A., Saidin, M.I., Mohd Nasir, M.N., Aris, T., Sinkins, S.P, Introduction of *Aedes aegypti* mosquitoes carrying *wAlbB Wolbachia* sharply decreases dengue incidence in disease hotspots, *ISCIENCE* (2024), doi: <https://doi.org/10.1016/j.isci.2024.108942>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 The Author(s).



Journal Pre-proof

1 **Introduction of *Aedes aegypti* mosquitoes carrying wAlbB *Wolbachia* sharply**
2 **decreases dengue incidence in disease hotspots**

3
4 Ary A. Hoffmann*, Pest and Environmental Research Group, School of BioSciences,
5 The University of Melbourne, Vic 3010, Australia

6 Nazni Wasi Ahmad, Medical Entomology Unit, Infectious Disease Research Centre,
7 Institute for Medical Research, Jalan Pahang, 50588 Kuala Lumpur, Malaysia

8 Wan Ming Keong, Vector Borne Disease Control Section, Disease Control Division,
9 Ministry of Health Malaysia, Complex E, Block E10, Persiaran Sultan Sallahuddin
10 Abdul Aziz Shah, Presint 1, 62000 Putrajaya, Malaysia

11 Cheong Yoon Ling, Biomedical Museum Unit, Special Resource Centre, Institute for
12 Medical Research, Jalan Pahang, 50588 Kuala Lumpur, Malaysia

13 Noor Afizah Ahmad, Medical Entomology Unit, Infectious Disease Research Centre,
14 Institute for Medical Research, Jalan Pahang, 50588 Kuala Lumpur, Malaysia

15 Nick Golding, Telethon Kids Institute, Perth Children's Hospital, Nedlands WA 6009;
16 Curtin School of Population Health, Curtin University, Bentley, WA 6845, Australia;
17 Melbourne School of Population and Global Health, University of Melbourne,
18 Parkville, VIC 3052, Australia

19 Nicholas Tierney, Telethon Kids Institute, Perth Children's Hospital, Nedlands WA
20 6009; Curtin School of Population Health, Curtin University, Bentley, WA 6845,
21 Australia

22 Jenarun Jelip, Vector Borne Disease Control Section, Disease Control Division,
23 Ministry of Health Malaysia, Complex E, Block E10, Persiaran Sultan Sallahuddin
24 Abdul Aziz Shah, Presint 1, 62000 Putrajaya, Malaysia

25 Perada Wilson Putit, Vector Borne Disease Control Section, Disease Control
26 Division, Ministry of Health Malaysia, Complex E, Block E10, Persiaran Sultan
27 Sallahuddin Abdul Aziz Shah, Presint 1, 62000 Putrajaya, Malaysia

28 Norhayati Mokhtar, Vector Borne Disease Control Section, Disease Control Division,
29 Ministry of Health Malaysia, Complex E, Block E10, Persiaran Sultan Sallahuddin
30 Abdul Aziz Shah, Presint 1, 62000 Putrajaya, Malaysia

31 Sukhvinder Singh Sandhu, Petaling District Health Office, Ministry of Health
32 Malaysia, SS 6, 47301 Petaling Jaya, Selangor, Malaysia

33 Lau Sai Ming, Petaling District Health Office, Ministry of Health Malaysia, SS 6,
34 47301 Petaling Jaya, Selangor, Malaysia

35 Khadijah Khairuddin, Petaling District Health Office, Ministry of Health Malaysia, SS
36 6, 47301 Petaling Jaya, Selangor, Malaysia

- 37 Kamilan Denim, Vector Borne Disease Control Section, Disease Control Division,
38 Ministry of Health Malaysia, Complex E, Block E10, Persiaran Sultan Sallahuddin
39 Abdul Aziz Shah, Presint 1, 62000 Putrajaya, Malaysia
- 40 Norazman Mohd Rosli, Health Department of Federal Territory of Kuala Lumpur &
41 Putrajaya, Jalan Cenderasari, 50590 Kuala Lumpur, Malaysia
- 42 Hanipah Shahar, Health Department of Federal Territory of Kuala Lumpur &
43 Putrajaya, Jalan Cenderasari, 50590 Kuala Lumpur, Malaysia
- 44 Topek Omar, Health Department of Federal Territory of Kuala Lumpur & Putrajaya,
45 Jalan Cenderasari, 50590 Kuala Lumpur, Malaysia
- 46 Muhammad Kamarul Ridhuan Ghazali, Medical Entomology Unit, Infectious Disease
47 Research Centre, Institute for Medical Research, Jalan Pahang, 50588 Kuala
48 Lumpur, Malaysia
- 49 Nur Zatil Aqmar Mohd Zabari, Medical Entomology Unit, Infectious Disease
50 Research Centre, Institute for Medical Research, Jalan Pahang, 50588 Kuala
51 Lumpur Malaysia
- 52 Mohd Arif Abdul Karim, Medical Entomology Unit, Infectious Disease Research
53 Centre, Institute for Medical Research, Jalan Pahang, 50588 Kuala Lumpur,
54 Malaysia
- 55 Mohamad Irwan Saidin, Medical Entomology Unit, Infectious Disease Research
56 Centre, Institute for Medical Research, Jalan Pahang, 50588 Kuala Lumpur,
57 Malaysia
- 58 Muhammad Nizam Mohd Nasir, Medical Entomology Unit, Infectious Disease
59 Research Centre, Institute for Medical Research, Jalan Pahang, 50588 Kuala
60 Lumpur, Malaysia
- 61 Tahir Aris, Institute for Medical Research, National Institutes of Health, Ministry of
62 Health Malaysia, Jalan Setia Murni U13/52, Seksyen U13, 40170 Shah Alam,
63 Selangor, Malaysia
- 64 Steven P Sinkins, MRC-University of Glasgow Centre for Virus Research, Glasgow,
65 UK
- 66 *lead author: ary@unimelb.edu.au

67

68 **Summary**

69 Partial replacement of resident *Aedes aegypti* mosquitoes with introduced
70 mosquitoes carrying certain strains of inherited *Wolbachia* symbionts can result in
71 transmission blocking of dengue and other viruses of public health importance.

72 *Wolbachia* strain *wAlbB* is an effective transmission blocker and stable at high
73 temperatures, making it particularly suitable for hot tropical climates. Following trial
74 field releases in Malaysia, releases using *wAlbB Ae. aegypti* have become
75 operationalized by the Malaysian health authorities. We report here on an average
76 reduction in dengue fever of 62.4% (confidence intervals 50-71%) in 20 releases
77 sites when compared to 76 control sites in high rise residential areas. Importantly the
78 level of dengue reduction increased with *Wolbachia* frequency, with 75.8% reduction
79 (61-87%) estimated at 100% *Wolbachia* frequency. These findings indicate large
80 impacts of *wAlbB Wolbachia* invasions on dengue fever incidence in an operational
81 setting, with incidence expected to further decrease as wider areas are invaded.

82

83 **Introduction**

84 *Wolbachia* are common symbiotic, inherited intracellular bacteria that can manipulate
85 the reproduction of their arthropod hosts, allowing them to invade populations. The
86 mosquito *Aedes aegypti*, the primary vector of dengue virus (DENV) and several
87 other arboviruses, does not naturally carry the symbiont¹; following laboratory
88 introduction into this species however, some *Wolbachia* strains are able to block the
89 transmission of DENV. Releases of *Wolbachia*-carrying *Ae. aegypti* were first
90 initiated in north-eastern Australia in 2010² with the aim of replacing *Wolbachia*-free
91 populations with populations carrying a high frequency of this bacterium, and thus
92 decrease the transmission of DENV (e.g.^{3,4,5}). The initial releases were undertaken
93 with a *Wolbachia* strain (*wMel*) that originated in *Drosophila melanogaster*². Since
94 that time releases have also been initiated with other *Wolbachia* including the *wAlbB*
95 strain originating in *Aedes albopictus*, which causes similar levels of virus
96 transmission blockage in multiple population backgrounds^{3,4,6,7}. Virus blockage with
97 a different *wAlbB* variant has been found to vary between genetic backgrounds⁸.
98 Both invasions of *wMel* and *wAlbB* have had a substantial impact on the local
99 incidence of dengue fever^{6,7,9-11}. However, in some areas there have been issues in
100 achieving and maintaining the high *Wolbachia* population frequencies in *Ae. aegypti*
101 that are necessary for effective disease control^{7,9,12}.

102 For *wMel*, local transmission cycles of seasonally imported DENV have been
103 virtually eliminated in *Wolbachia*-invaded areas in Australia¹⁰. In Yogyakarta in
104 Indonesia¹¹ where dengue is endemic there has been an estimated 77% reduction
105 in dengue fever incidence following releases. Releases of *wAlbB* in dengue hotspots
106 that acted as initial release sites resulted in an estimated decrease in dengue of
107 40.3% compared to control sites around the Kuala Lumpur region⁹. Reductions have
108 been obtained using *wMel* in sites around Rio de Janeiro where invasion has been
109 challenging, with *Wolbachia* frequencies often failing to reach 50% in *Ae. aegypti*
110 populations and averaging 38%⁶.

111 The relative success of these interventions at research sites despite some
112 challenges has increased interest around the world from health authorities wanting to
113 use *Wolbachia* releases routinely to suppress dengue fever. A range of *wMel* and
114 *wAlbB* *Wolbachia* strains as well as others are starting to be developed for in country
115 use (e. g. ^{13,14}). Releases have been initiated in multiple locations around the world
116 with local resources, and cost-effectiveness analyses have been completed to
117 support the widescale use of this technology ¹⁵.

118 In Malaysia, releases have focused on a *Wolbachia* *wAlbB* strain introduced into a
119 local genetic background ⁴. The *Wolbachia* Malaysia project was launched in 2017,
120 releasing *wAlbB*-carrying *Ae. aegypti* in 11 dengue hotspots in the Klang Valley
121 around Kuala Lumpur ⁹. Since then, *Wolbachia* density and frequency as well as
122 dengue blocking ability have remained stable in many of the original release areas
123 ^{16,17}.

124 Because of the promising effect of the initial releases in reducing dengue incidence,
125 the Disease Control Department of the Malaysian Ministry of Health, in collaboration
126 with the Institute for Medical Research Malaysia, deployed *Wolbachia*-carrying *Ae.*
127 *aegypti* to various additional dengue hotspot localities around Kuala Lumpur in a
128 move to make *Wolbachia* releases part of the normal operations the government
129 takes against dengue fever. These activities coupled with ongoing monitoring at
130 some of the original release sites (Figure 1) and the availability of long-term data on
131 dengue fever incidence provide a unique opportunity to reassess impact on dengue
132 fever incidence associated with *wAlbB* invasion. They also provide an opportunity to
133 assess the impact of different *Wolbachia* frequencies attained at sites on dengue
134 fever incidence.

135

136 Results

137 *Wolbachia* invasion and persistence

138 Because releases were started in different areas at different times, changes in
139 *Wolbachia* frequency are presented as weeks since the releases were initiated
140 (Figure 2). The weeks when releases were undertaken are also presented on these
141 graphs. *Wolbachia* frequencies increased rapidly at some sites and stayed high
142 (W16, W17, W21, W24) which included two research sites. At others (W03, W05,
143 W07, W10, W11, W19) they increased more slowly to reach a high frequency. At still
144 others (W22, W27) there seemed to be a period of instability before frequencies
145 settled at a high level. The remaining sites such as W02 and W15 showed instability
146 which contributed to subsequent releases being undertaken (as marked on the
147 graphs). Some of this instability may have reflected small sample sizes although
148 points are based on a minimum of 10 individuals. Moreover, for some sites showing
149 variable *Wolbachia* frequencies like W22 and W15, the average mosquito numbers
150 scored per monitoring point was relatively high (280.2 and 167 respectively) whereas

151 the site (W26) with the lowest average number of mosquitoes per monitoring point
152 (40.2) showed a consistent pattern of change in *Wolbachia* frequency.

153

154 *Dengue impact*

155 Across all 20 release sites, the mean *Wolbachia* frequency in the release + post-
156 release monitoring period averaged 82.3%, ranging from 56.2% to 96%. A Bayesian
157 model provided the posterior mean estimate of the reduction in dengue fever
158 incidence at this average *Wolbachia* frequency of 62.4% (95% credible interval: 50-
159 71% reduction), ranging from a 42.6% (95% CI: 34-49%) decrease in the lowest-
160 frequency site to a 72.8% (95% credible interval: 59-83%) decrease in the highest
161 frequency site. At a hypothetical 100% *Wolbachia* frequency, the model estimated a
162 posterior mean reduction in dengue incidence of 75.8%, with a 95% credible interval
163 from 61-87%. Table 1 summarises the posterior distributions over the model
164 parameters. The posterior probability of *Wolbachia* releases resulting in a reduction
165 in dengue incidence was greater than 0.999.

166

167

168 **Discussion**

169 With the additional release sites and extended period of dengue fever monitoring, we
170 find stronger evidence for dengue reduction following release of *wAlbB*-carrying
171 mosquitoes than recorded in our earlier work⁹, particularly at high *Wolbachia*
172 frequencies in release sites. At some research sites like Mentari Court and S7
173 Commercial, dengue fever cases have now been reduced for a number of years and
174 the *Wolbachia* has remained stably high without further releases; in high rise blocks
175 at Mentari Court, the *Wolbachia* also remains well spread throughout the apartment
176 blocks where interventions took place^{9,17}. Dengue reduction has persisted despite
177 no further community engagement in these sites. Clearly as *Wolbachia* frequencies
178 stabilise in new areas there is the potential for further increasing the impact of the
179 infection on dengue fever cases.

180 The level of dengue fever reduction is similar to that achieved in Yogyakarta with
181 *wMel* where the *Wolbachia* frequency in invaded areas was 95.8%¹¹ although that
182 project employed releases over larger areas in a randomised design rather than
183 through an operationalized approach aimed at specific areas where dengue was
184 common. *Wolbachia* frequencies in large, invaded areas are expected to be more
185 stable than small areas since there is a lower likelihood of movement of *Wolbachia*-
186 free mosquitoes into an area¹⁸, although this will also depend on the structure of the
187 urban environment including the presence of wide roads¹⁹. DENV will be acquired
188 outside release areas and contribute to the local incidence of dengue fever in an
189 area, making it less likely to detect large reductions in small areas. While the
190 incidence of dengue fever reduction in some areas have been more moderate than

191 achieved with *wMel* in Yogyakarta, such as a 38% reduction in Rio de Janeiro ⁶, the
192 *wMel Wolbachia* incidence was also lower in this area at 33.8% overall.

193 There was a substantial impact of *Wolbachia* frequency on dengue reduction with
194 the Bayesian model indicating a strong overall negative association between
195 *Wolbachia* frequency and dengue fever incidence. This pattern was clear at sites
196 such as W05, W08 and W10, where the *Wolbachia* frequency was relatively low
197 reflecting a slow invasion or instability in *Wolbachia* frequencies (Figure 2), while the
198 incidence of dengue fever remained relatively high after releases started (Figure 3).
199 The reverse pattern was evident at other sites like W16, W17, and W24, although
200 W15 was an exception. Overall, these findings highlight the importance of continued
201 *Wolbachia* monitoring and taking the necessary steps when there is a decrease in
202 *Wolbachia* frequencies. Booster releases were successful in re-establishing or
203 maintaining high frequencies (such as locations Kelana and Subang in Figure 2) but
204 this does entail ongoing monitoring of release sites.

205 The reasons for the observed variation in *Wolbachia* stability remain unclear, with no
206 obvious connection to any of the variables defining the release sites (Table 1).
207 However, it is consistent with data from release programs in other countries that
208 highlight variable success in obtaining introductions which include slow increases in
209 some populations ^{6,20}. Identifying the factors involved remains an intriguing area for
210 future research, with a number of factors that could be important such as
211 environmental conditions, local mosquito movement patterns (including immigration
212 from neighbouring areas such as construction sites with high mosquito density), and
213 the nature of breeding sites (predominance of permanent versus temporary,
214 periodically inundated breeding sites, which will affect *Wolbachia* fitness costs)
215 ^{12,21,22}. Ongoing fogging in neighbourhoods adjacent to release sites is another
216 possibility. Theory also emphasizes the importance of density dependent interactions
217 ²³. A combination of local *Wolbachia* and entomological monitoring as well as
218 molecular approaches such as tracking mtDNA variation ²⁴ and new ways of tracking
219 breeding sites ²⁵ could provide useful tools in developing this understanding.

220 The outcome of this research program followed by an expanded operational program
221 serves as the basis for future expansion of releases in additional dengue-prone
222 areas. To date a total of 40 localities inclusive of research sites have been used for
223 releases with *Ae. aegypti* carrying *wAlbB Wolbachia* in 8 states in Malaysia. The
224 Malaysian Ministry of Health has established plans for future release of *Wolbachia*
225 mosquitoes in dengue hotspots as a national rollout program. The results support the
226 continued use of *wAlbB* in the Kuala Lumpur area, where temperatures in breeding
227 sites can be high, so the proven strong stability of *wAlbB Wolbachia* under hot
228 conditions ^{26,27} remains important.

229

230 **Limitations of the Study**

231 Because of the operationalized nature of the releases, we were unable to
232 successfully randomise control and release sites prior to the start of the study. When
233 health authorities are tackling dengue fever outbreaks with limited resources, the
234 focus is on responding rapidly to existing outbreaks as well as local community
235 pressure. This prevented the adoption of a “gold standard” intervention design.
236 Because of funding restrictions, we also relied on local health officers with different
237 levels of experience in undertaking mosquito releases and establishing a trapping
238 network, rather than being able to use the same team for releases and monitoring in
239 all areas. Finally, we were required to change the nature of the releases in several
240 areas due to restrictions imposed by the covid outbreak (see Methods).
241 Nevertheless, these limitations are in some ways also the strength of the study which
242 provides an indication of the level of dengue fever suppression one might expect to
243 be achieved by *wAlbB* invasion in a realistic setting.

244

245 **Acknowledgments**

246 Funding for the study was provided by Wellcome Trust Awards 226166, 108508,
247 202888 and Ministry of Health Malaysia NMRR-16-297-28898. The authors thank
248 the Director General of Health, Ministry of Health, Malaysia, for permission to
249 publish. We acknowledge Datuk Dr Norhayati binti Rusli, Deputy Director General of
250 Health (Public Health), Ministry of Health, Datuk Dr Rose Nani Mudin, and Mohd
251 Khairuddin Che Ibrahim for the continuous support throughout the project.

252

253 **Author contributions**

254 Conceptualization, A.A.H., N.W.A. S.P.S., T.A., W.M.K.; Methodology, N.W.A.,
255 A.A.H., S.P.S., C.Y.L.; Investigation, N.W.A, N.A.A., J.J., P.W.T., N.M., S.S.S.,
256 L.S.M., K.K., K.D., N.M.R., H.S., T.O., M.K.R.G., N.Z., M.A.A.K., M.I.S., M.N.M.N.;
257 Formal Analysis, N.G., N.T., C.Y.L., A.A.H.; Visualisation: N.G., N.T., C.Y.L.; Writing
258 – Original Draft, A.A.H., S.P.S., N.W.A., N.G.; Writing – Review & Editing, A.A.H.,
259 S.P.S., N,W,A; Funding Acquisition, S.P.S., T.A., W.M.K.; Resources, S.P.S., T.A.,
260 W.M.K.; Supervision, N.W.A., M.K.R.G., N.A.A.; Management, N.W.A.,T.A., W.M.K.,
261 S.P.S., A.A.H.

262

263 **Declaration of Interests**

264 The authors declare that they do not have conflicting interests.

265

266 **Figure titles and legends**

267 Figure 1. Map of Selangor region showing operational release sites used in
 268 evaluating *Wolbachia* impact and control sites. Districts within the region are
 269 labelled. Release sites are marked (see Table S1 for code).

270 Figure 2. Changes in the frequency of *Wolbachia* across time in the release sites.
 271 The sites with similar patterns of *Wolbachia* changes are grouped together.
 272 Frequency estimates are based on a minimum of 10 adults being screened. Periods
 273 of mosquito release are also indicated on the graphs along the bottom colour coded
 274 for each release site.

275 Figure 3. Incidence of dengue in sites the 20 release sites. Data are black dots, the
 276 posterior mean predicted incidence is represented by the black lines, with the 95%
 277 predictive interval in grey. The period of *Wolbachia* release and mean frequency of
 278 *Wolbachia* are also provided (blue region; first level is the release period, second is
 279 after releases finished).

280

281 Tables

282

283 Table 1. Parameter estimates for variables in the model estimating *Wolbachia*
 284 release effects.

285

Parameter	Posterior mean	95% credible interval
ρ (autoregression parameter in the random timeseries model for weekly dengue cases)	0.937	0.93 - 0.94
σ (noise parameter in the random timeseries model for weekly dengue cases)	0.482	0.47 - 0.5
β (proportional change in dengue cases if <i>Wolbachia</i> is at 100%)	-0.758	-0.87 - -0.61

286

287

288

289 **STAR Methods**

290

291

292 **Resource Availability**

293 LEAD CONTACT

294

- 295 • Further information and requests for resources should be directed to and will
296 be fulfilled by the lead contact, Ary Hoffmann (ary@unimelb.edu.au).
- 297 • For enquiries about the *Ae. aegypti*-wAlbB line, contact Steven Sinkins
298 (steven.sinkins@glasgow.ac.uk).

299

300 MATERIALS AVAILABILITY

301

- 302 • This study did not generate new unique reagents.
- 303 • There are MTA restrictions to the availability of the *Ae. aegypti*-wAlbB line,
304 due to collaborative agreements put in place to ensure all further releases of
305 this line are conducted in a carefully controlled manner.

306

307 DATA AND CODE AVAILABILITY

- 308 • Dengue and *Wolbachia* data are available as MS Excel sheets in a public
309 repository at <https://doi.org/10.26188/24314689.v1>.
- 310 • R code for Bayesian analysis is freely available at
311 https://github.com/goldingn/wolbachia_kl.
- 312 • Any additional information required to reanalyze the data reported in this
313 paper is available from the lead contact upon request.

314

315

316 EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

317

318 The wAlbB *Wolbachia* line that formed the basis for the releases had previously
319 been produced by microinjection⁴ into an uninfected *Aedes aegypti* line originating
320 from Kuala Lumpur. The line was transferred from Glasgow University to the Institute
321 for Medical Research, Kuala Lumpur, where backcrosses were undertaken prior to
322 mass rearing to maximize the fitness and competitiveness of the mosquitoes to be
323 released.

324

325 All aspects of rearing the mosquitoes and quality control follow the description in
326 Nazni et al.⁹ with minor modifications. Briefly, weighed eggs from colonies were
327 submerged in seasoned tap water (after desiccation) and exposure to an air vacuum
328 to stimulate hatching. The seasoned water consisted of tap water stored overnight to
329 dechlorinate the water. Eggs were hatched in beakers with the seasoned water.

330 These eggs were used to mass rearing and for release where egg containers were

331 used. In other releases, adults rather than eggs were released and eggs were
332 shipped to local field workers to produce the adults. Quality control measures during
333 culture included wing measurements.

334 Releases were undertaken as part of a program (the “operational program”) run by
335 the Ministry of Health targeting multi-storey buildings where dengue incidence was
336 historically high. This program followed the successful introduction of *Wolbachia* at
337 research sites which was described in Nazni et al. ⁹. The *Wolbachia* operational
338 program started on 7 July 2019 and has been undertaken in several phases as
339 resources and other factors such as COVID lockdown have allowed. The operational
340 program has so far targeted 40 sites but here we focus on 15 sites as well as five
341 sites from the initial research program where continued monitoring has taken place
342 and where there is an adequate elapsed time for dengue monitoring since releases
343 have started. Changes in dengue incidence at these sites was compared to those
344 recorded at 76 control sites consisting of high dengue areas close to the release
345 sites which also consisted of multi-storey developments (Figure 1).

346 A fundamental requirement for successful implementation of a mosquito release
347 program is community engagement involving comprehensive education of the local
348 community. This ensures that the community appreciates the underlying objectives
349 and strategies associated with the release initiative. The engagement efforts were
350 undertaken by the Institute of Behavioural Research (IPTK) in collaboration with the
351 Institute of Medical Research (IMR).

352 Following releases, *Wolbachia* frequencies were assessed using mosquito larvae
353 collected with 100 ovitraps per release site. Mosquitoes were identified to species
354 and *Wolbachia* status was assessed through qPCR. Dengue data for each site was
355 obtained from the Disease Control Division, Ministry of Health, with each recorded
356 dengue case confirmed by clinical and laboratory criteria. A Bayesian time series
357 analysis was used to assess the impact of *Wolbachia* releases on dengue fever
358 incidence following Nazni et al. ⁹ but with a consideration of *Wolbachia* frequency
359 averaged across the release and post-release period.

360 METHOD DETAILS

361 *Mosquito culture*

362 For mass rearing adults, mosquito eggs were laid on paper and around 15000 eggs
363 estimated by weight were soaked in 1 l of seasoned water in a 36 x 26 x 5.5 cm
364 container. Two days after the hatching process, the larvae were filtered and put into
365 a beaker containing 500 ml of seasoned water and 10 aliquots of larvae (1 ml per
366 aliquot) were taken from the beaker using a 10 ml plastic pipette (approximately 50
367 larvae per 1 ml aliquot). 10 of these aliquots were placed into a 36 x 26 x 5.5 cm
368 plastic container with 1 l of seasoned water. Sera Vipan powder (Heinsberg,
369 Germany) was given daily to ensure even pupation.

370 To separate sexes, 12,000 larvae and pupae were introduced into a pupal
371 separation system (Orinno Technologies, Singapore). These immature stages were
372 separated over a period of around 13 min, producing groups of separated (mostly)
373 male pupae, (mostly) female pupae and larvae.

374 For producing the next generation of the stock population of mosquitoes, we used
375 3750 female and 1250 male pupae which were transferred to a plastic container
376 filled with seasoned water and placed in a mosquito cage (30.5 x 30.5 x 30.5 cm) to
377 emerge into adults. Emerged mosquitoes were fed on laboratory-reared mice before
378 oviposition on paper to restart the process. Wing measurements were carried out
379 periodically for quality control and wild type males collected from field stock were
380 introduced every 7 generations to ensure fresh material entered the culture regularly.

381

382 *Operational program*

383 Phase 1 of the operational program involved releasing eggs in containers provided to
384 the Ministry of Health field workers. Two other phases have since been added,
385 resulting in 40 sites now where releases have been conducted. The focus here is on
386 the first 15 operational sites representing the first two operational phases and the 5
387 sites from the original program⁹ where sufficient *Wolbachia* and dengue data is
388 available across 5 years to test for intervention effects.

389 *Wolbachia* release areas in the Selangor region (Figure 1) were based on selection
390 criteria important to local health staff and managers which focused on the incidence
391 of dengue, presence of mosquitoes, and perceived barriers (mostly roads) around
392 the release sites given that most movement of mosquitoes tends to be within
393 buildings c. f.²⁸. The majority of the research sites, and thirteen operational release
394 sites were situated in Selangor, while five sites were in Kuala Lumpur and two sites
395 were in Putrajaya.

396 Release sites (Supplementary Table S1) consisted of areas that varied in size
397 (19,321 to 276,261 m²) where *Ae. aegypti* numbers were relatively high (index value
398 derived from the proportion of positive ovitraps placed for 7 days in an area > 40%).
399 Sites with a high *Aedes aegypti* index and low *Ae. albopictus* index were preferred.
400 For each defined area constituting a site, data on the incidence of dengue cases
401 across the previous 5 years were collected, along with information on the relative
402 abundance of *Ae. aegypti* and *Ae. albopictus* mosquitoes (based on prior ovitrap
403 surveillance).

404 For each individual site nominated by authorities, a site profile was generated in
405 terms of the number of residential housing blocks, number of stories, whether the
406 area was treated with outdoor residual sprays and whether it was surrounded by any
407 potential barriers to mosquito movement, particularly multi-lane highways or
408 vegetated areas.

409 *Community engagement*

410 Community members were regularly invited to IMR and provided with transparent
411 updates of release progress. Community members were encouraged to be actively
412 engaged in discussions to encourage shared responsibility and ownership. The local
413 community were positive about the release of both male and female *Wolbachia*
414 infected mosquitoes as a way of suppressing dengue and in many cases the
415 mosquitoes encountered after releases were viewed as “good” mosquitoes with a
416 reluctance to kill them even though continued local steps to control were encouraged
417 by engagement staff. The significant reduction in dengue cases within release areas
418 instilled a sense of protective custodianship which led to communities becoming
419 strong advocates for the continuation of the *Wolbachia* program.

420 A novel communication tool involved the creation of a WhatsApp group to facilitate
421 exchange of ideas, insights, and concerns within the community. Members sought
422 clarifications, shared observations and engaged in dialogues that helped foster
423 collective commitment to disease prevention. This contributed to vigilance in the
424 community about pesticide fogging activities near to release areas communicated to
425 local health departments which often led to the cessation of fogging operations. This
426 represents a good example of community advocacy for the program. Community
427 champions emerged which shared firsthand experience of release related activities
428 and the insights of these community members extending to other release sites. In
429 control sites community engagement consisted of larval source reduction activities.

430 Three days prior to the first release, a program of fogging, larval control, breeding
431 site search and destroy activities, and health promotion activities were undertaken as
432 outlined for previous releases⁹. These are normal procedures carried out in dengue
433 hotspot areas as represented by the release and control sites assessed here. For
434 the promotion activities, brochures on the benefits of releasing *Aedes Wolbachia*
435 were generated and distributed to households.

436 *Operational releases*

437 Eggs were initially used in the operational releases but there was a switch to adults
438 later during the COVID -19 period (below). We aimed to release a total of 10
439 mosquitoes per house unit per week, with equal numbers of males and females
440 being released. The number of eggs released was always double this number, with
441 the expectation that 50% of the eggs would not hatch due for example to predation
442 of eggs and adults emerging from egg release containers (see below).

443 For egg releases, 200 eggs were introduced into a release container as described in
444 Nazni et al.⁹. Egg containers were placed in sites within buildings such as
445 passageways and staircases to ensure minimum disturbance by the community, and
446 in shaded spots to avoid direct exposure to sunlight, which can result in high larval
447 mortality. Egg release containers were visited 3 times; on day 2 after placement to
448 introduced food for larvae, on day 5 to open the stoppers or lids for adults to escape

449 into the open, and on day 7 to collect the egg release containers and to replace
450 these with another set of egg release containers.

451 The switch from eggs to adults related to the fact that the early release period
452 coincided with COVID-19 pandemic, whereby the several phases of control on the
453 human population were present. The Movement Control Order (MCO) was
454 implemented, then the Conditional Movement Control Order (CMCO) and Recovery
455 Movement Control Order (RMCO) until the end of May 2021. During the MCO, only
456 key government and private services were allowed to operate, while the CMCO and
457 RMCO aimed to revive the economy while implementing social distancing measures
458 to effectively curb the progression of the pandemic. Standard operating procedures
459 (SOPs) and guidelines consisting of health and safety measures was issued by the
460 Malaysian National Security Council via mass media using radio, television,
461 newspapers, government websites, social media, and text messages. During the
462 MCO, the 3Cs (Crowded places, Confined spaces, Close conversation) and applying
463 the 3Ws (Wash hands, Wear masks, Watch your distance, were strictly followed.
464 Due to the introduction of MCO, egg releases were no longer possible and were
465 changed to adult releases to reduce issues around communication and social
466 distancing by MOH staff releasing the *Wolbachia* mosquitoes.

467 For adult releases, eggs were provided by IMR to the Botanic Laboratory Selangor
468 (Ministry of Health) where eggs were hatched and reared to the adult stage, with
469 releases involving 3-day-old adults (sexes mixed) held in small containers as
470 described in Nazni et al. ⁹.

471

472 *Research and control sites*

473 Monitoring continued at 5 of the release sites involving multistorey buildings
474 described in Nazni et al ⁹. This included *Wolbachia* monitoring yearly in Mentari
475 Court, 6 monthly Flat A, B and C in Shah Alam, and 3-monthly in Section 7
476 Commercial Centre (see Results).

477 The control sites were selected to match operational and research sites in terms of
478 involving multi-story residential buildings with a similar area size and population size
479 (Supplementary Table S1) as well as dengue burden. The control sites were
480 selected based on the highest dengue burden districts with prolonged outbreaks in
481 Malaysia, the districts Hulu Langat, Gombak, Petaling and Klang in Selangor. The
482 ratio of intervention sites to the control sites was ideally set as at least 1:3. We
483 collated the 353,683 reported dengue cases of all four districts from 2014 till 2021.
484 The data was grouped by locality and sorted from highest to lowest total dengue
485 cases according to three time periods, i. e. year 2014 till 2018, 2015 till 2019 and
486 2016 till 2020, as the release of *Wolbachia* mosquitoes in the intervention sites were
487 started in different phases. The intervention sites were then matched based on high
488 dengue burden, high rise building type and pre-release time period. Seventy-six

489 control sites were identified by the Vector Control Department (Figure 1). However
490 matched groupings had no impact on dengue reduction effects when included in the
491 Bayesian models (below) so only analyses based on pooled control site data are
492 presented.

493

494 *Wolbachia* monitoring

495 Each ovitrap for collecting mosquitoes consisted of a plastic container (96 mm
496 height, 67 mm diameter) with 150 mL water and a wooden paddle (2 cm x 7 cm). In
497 all *Wolbachia* release operational localities and research localities, 100 ovitraps were
498 set up in the apartment buildings. The ovitraps were spread across every 2-3 floors.
499 If there were carparks for the respective buildings, ovitrap were placed on alternate
500 floors. Ovitrap were collected after a week and the paddle + water was transferred
501 to a plastic container (12 x 3 x 12 cm). All emerging mosquitoes were identified to
502 species and a maximum of 5 *Ae. aegypti* per trap were used for *Wolbachia*
503 screening. *Wolbachia* frequency was only computed in releases (with three
504 exceptions, 2 from W26 (with n=5) and 1 from W27 (with n=7) if at least 10 adults
505 were scored from the ovitraps (with a maximum of 500 possible given that 100 traps
506 were placed at each locality).

507 In all operational release sites, monitoring was done after 4 weeks from the first
508 release. To ensure that the release procedures and subsequent activities were
509 consistent across operational locations, a Standard Operation Procedure (SOP) for
510 adult releases was developed, involving six stages and implemented as required: (i)
511 an initial release phase; (ii) an ongoing monitoring phase; (iii) booster releases as
512 required; (iv) a second monitoring phase; (v) further booster releases as required;
513 and (vi) a maintenance phase. Adult releases and egg releases were stopped when
514 frequency of *Wolbachia* in field population reached 80% and remained at 80% or
515 more for 3 consecutive monitoring periods across 3 months. Monitoring was
516 undertaken irregularly after that period while research sites were also irregularly
517 monitored.

518 Adults from ovitraps were stored in absolute ethanol at - 80°C. DNA was extracted
519 from individual mosquitoes using a glass bead and Chelex solution in an extraction
520 tube. Mosquitoes were homogenized in 175 µL of 5% Chelex solution using
521 TissueLyser II machine (QIAGEN) and with 5 µL of proteinase K (20 mg/mL) (Bioron
522 Life Science). The extraction plate was spun down at 4000 rpm for 5 mins and the
523 mosquito aliquot was transferred into 96 plates and spun down again for another 5
524 minutes. The extraction was incubated in a thermocycler at 65°C for 1 hour, followed
525 by incubation for 10 min at 90°C. The plate was removed and spun down for another
526 5 mins. *Wolbachia* was detected by high-resolution melting polymerase chain
527 reaction (qPCR-HRM)²⁷ with 1:10 diluted DNA using the following wAlbB1-specific
528 primers: wAlbB1-F (50-CCTTACCTCCTGCACAACAA) and wAlbB1-R (50 –

529 GGATTGTCCAGTGGCCTTA), as well as universal mosquito primers: mRpS6_F
530 (50-AGTTGAACGTATCGTTT CCCGCTAC) and mRpS6_R (5 0 -
531 GAAGTGACGCAGCTTGTGGTCGTCC), which target the conserved region of the
532 RpS6 gene, and *Ae. aegypti* primers aRpS6-F (5 0 -ATCAAGAAGCGCCGTGTGCG)
533 and aRpS6-R (5 0 -CAGGTGCAGGATCTTCATGTATTG), which target the *Ae.*
534 *aegypti*-specific polymorphisms within RpS6 and do not amplify *Ae. albopictus*.

535 Reactions were run as 384-well plates in a LightCycler 480 II (Roche). qPCR-HRM
536 was performed in 10 μ L reactions containing 2 μ L of DNA, 0.08 μ L of 50 mM forward
537 + reverse primer, 2.92 μ L Milli-Q water and 5 μ L Ronald's Real-Time Buffer (3.28 μ L
538 Milli-Q water, 0.4 μ L MgCl₂ (50 mM), 1.0 μ L ThermoPol Reaction Buffer with 20 mM
539 Magnesium (10x), 0.25 μ L HRM Master (Roche), 0.064 μ L dNTPs (25 mM) and 0.01
540 μ L Immolase (20 U/ μ L). qPCR was run following cycling conditions: 95°C for 10 min,
541 followed by 50 cycles of 95°C for 10 s, 58°C for 15 s, 72°C for 15 s. High resolution
542 melting was performed by heating the PCR product to 95°C, and then cooling to
543 40°C. Then the temperature was increased to 65°C. Samples were considered
544 positive for *Wolbachia* when the T_m for the amplicon produced by the *Ae. aegypti*
545 primers was at least 84°C and the T_m for the *Wolbachia*-primer amplicon was
546 around 80°C.

547

548 *Dengue data*

549 The dengue incidence for both intervention sites (Figure 3) and control sites
550 (Supplementary Figures S1-S4) were obtained starting from 2013. Based on
551 guidelines published by Disease Control Division, namely the Case Definition for
552 Infectious Diseases in Malaysia (2017), a confirmed dengue case was defined as
553 fulfilling both the clinical and laboratory criteria. Clinical criteria include acute onset of
554 high-grade fever of 2-5 days associated with 2 or more clinical features such as
555 headache, retro-orbital pain myalgia, arthralgia, rash and mild haemorrhagic
556 manifestation. All patients presented with relevant symptoms and be diagnosed with
557 suspected dengue will be notified by attending doctor and confirmatory laboratory
558 test will be conducted. The laboratory criteria for dengue included detection of
559 dengue non-structural protein 1 (NS1) or dengue antibody (IgM/IgG) or dengue virus
560 genome by PCR or dengue virus isolation from serum or dengue virus antigen in
561 tissue biopsy. Patients that tested positive for dengue with any of these tests are
562 registered in national dengue registry, also known as eDengue. Dengue combo rapid
563 test kits containing NS1 and IgM/IgG are used as point of care testing in most
564 government health clinics for early diagnosis and treatment.

565

566 QUANTIFICATION AND STATISTICAL ANALYSIS

577 A Bayesian time series model was used to estimate reduction in dengue cases as a
 578 result of the increased frequency of *Wolbachia* following releases. The model follows
 579 that in Nazni *et al.*⁹, but the reduction in dengue cases is modelled as proportional to
 570 the frequency of *Wolbachia*. The model structure was as follows:

$$\begin{aligned}
 571 \quad & y_{i,t} \sim \text{Poisson}(\lambda_{i,t}N_i) \\
 572 \quad & \ln(\lambda_{i,t}) = \alpha_i + \gamma_{i,t} + \log(1 + \beta x_i) \\
 573 \quad & \gamma_{i,t} = \rho \gamma_{i,t-1} + \epsilon_{i,t}; \gamma_{i,0} = 0 \\
 574 \quad & \epsilon_{i,t} \sim N(0, \sigma^2); \alpha_i \sim N(0, 10^2);
 \end{aligned}$$

575 with global parameter prior distributions:

$$576 \quad \rho \sim U(-1, 1); \sigma \sim N^+(0, 10^2); \log(1 + \beta) \sim N(0, 1^2)$$

577 where the number of cases y at each site i and week t were assumed to follow a
 578 Poisson distribution, with the expected count given by the product of population at that
 579 site (N), and the per-capita incidence (λ) which varied varying through time t and
 580 between sites. Each site i had a separate time series of log-incidences $\alpha_i + \gamma_{i,t}$ with
 581 temporal correlation driven by an autoregressive model of order one, with global
 582 parameters ρ and σ^2 describing the prior distribution shared by all sites. Each
 583 observation therefore had a separate temporally-correlated random effect on the log
 584 scale, to account for extra-Poisson dispersion and temporal correlation in case counts.
 585 Both release sites (including pre- and post-release periods) and non-release sites were
 586 included, enabling us to estimate expected levels of volatility in case count time series
 587 in this part of the model.

588 The intervention effect was represented by a parameter β and a covariate $x_{i,t}$ giving
 589 the mean frequency of *Wolbachia* in the mosquito population in each site and time.
 590 The values of $x_{i,t}$ were assumed to be constant over the release and post-release
 591 monitoring periods (set to the mean of observations) and set to 0 in pre-release times
 592 and in non-release sites. Model parameters were assigned vague priors with normal;
 593 positive-truncated normal; or uniform distributions. The $\log(1 + x)$ transformations
 594 applied to the intervention effect term ensures that the parameter β can be interpreted
 595 as the proportional change in dengue cases if *Wolbachia* frequency was at 100%,
 596 which is scaled linearly according to the achieved *Wolbachia* frequency; i.e. at a
 597 *Wolbachia* frequency of 100%, dengue cases are changed by percentage $100 * \beta$,
 598 whilst at a frequency of 25%, dengue cases are changed by percentage of $25 * \beta$. This
 599 choice of prior implies a median value of 0% change in dengue cases and a 50%
 600 interval ranging from a 49% reduction to a 96% increase in dengue cases. The model
 601 therefore assumes *a priori* that there is a 50% probability of *Wolbachia* presence
 602 reducing dengue cases, and a 50% probability of it increasing cases. The model was
 603 fitted to the dengue incidence data to estimate the impact of the releases, and to
 604 assess the evidence from the dengue case data that releases lead to a reduction in
 605 incidence - quantified as the posterior probability that β is negative.

606 Posterior samples of model parameters were simulated by Hamiltonian Monte Carlo in
 607 greta²⁹ with 4 chains, each yielding 4000 posterior samples of model parameters after
 608 a warmup period of 1000 iterations during which period the leapfrog step size and
 609 diagonal mass matrix parameters were tuned. The number of leapfrog steps was
 610 sampled uniformly from between 30 and 40 throughout. Convergence was assessed
 611 by the Gelman-Rubin \hat{R} diagnostic, using the coda R package³⁰ ($\hat{R} \leq 1.01$ for all
 612 parameters) and visual assessment of trace plots. Model fit was assessed by posterior
 613 predictive simulation: a random dataset of $y_{i,t}$ values was generated according to each
 614 posterior sample of $p_{i,t}$ and r , and the distributions of the simulated $y_{i,t}$ values were
 615 compared with the observed $y_{i,t}$. The analysis code is freely available online at
 616 https://github.com/goldingn/wolbachia_kl.

617

618

619 References

- 620 1. Ross, P.A., Callahan, A.G., Yang, Q., Jasper, M., Arif, M.A., Afizah, A.N., Nazni, W.A.,
 621 and Hoffmann, A.A. (2020). An elusive endosymbiont: Does *Wolbachia* occur
 622 naturally in *Aedes aegypti*? *Ecology and Evolution* *10*, 1581-1591.
- 623 2. Hoffmann, A.A., Montgomery, B.L., Popovici, J., Iturbe-Ormaetxe, I., Johnson, P.H.,
 624 Muzzi, F., Greenfield, M., Durkan, M., Leong, Y.S., Dong, Y., et al. (2011). Successful
 625 establishment of *Wolbachia* in *Aedes* populations to suppress dengue transmission.
 626 *Nature* *476*, 454-457. 10.1038/nature10356.
- 627 3. Flores, H.A., Taneja de Bruyne, J., O'Donnell, T.B., Tuyet Nhu, V., Thi Giang, N., Thi
 628 Xuan Trang, H., Thi Thuy Van, H., Thi Long, V., Thi Dui, L., Le Anh Huy, H., et al.
 629 (2020). Multiple *Wolbachia* strains provide comparative levels of protection against
 630 dengue virus infection in *Aedes aegypti*. *PLoS Pathogens* *16*, e1008433.
 631 10.1371/journal.ppat.1008433.
- 632 4. Ant, T.H., Herd, C.S., Geoghegan, V., Hoffmann, A.A., and Sinkins, S.P. (2018). The
 633 *Wolbachia* strain wAu provides highly efficient virus transmission blocking in *Aedes*
 634 *aegypti*. *PLoS Pathogens* *14*, e1006815. 10.1371/journal.ppat.1006815.
- 635 5. Hugo, L.E., Rasic, G., Maynard, A.J., Ambrose, L., Liddington, C., Thomas, C.J.E., Nath,
 636 N.S., Graham, M., Winterford, C., Wimalasiri-Yapa, B., et al. (2022). *Wolbachia* wAlbB
 637 inhibit dengue and Zika infection in the mosquito *Aedes aegypti* with an Australian
 638 background. *PLoS Neglected Tropical Diseases* *16*, e0010786.
 639 10.1371/journal.pntd.0010786.
- 640 6. Dos Santos, G.R., Durovni, B., Saraceni, V., Riback, T.I.S., Pinto, S.B., Anders, K.L.,
 641 Moreira, L.A., and Salje, H. (2022). Estimating the effect of the wMel release
 642 programme on the incidence of dengue and chikungunya in Rio de Janeiro, Brazil: a
 643 spatiotemporal modelling study. *The Lancet Infectious Diseases* *22*, 1587-1595.
- 644 7. Pinto, S.B., Riback, T.I.S., Sylvestre, G., Costa, G., Peixoto, J., Dias, F.B.S., Tanamas,
 645 S.K., Simmons, C.P., Dufault, S.M., Ryan, P.A., et al. (2021). Effectiveness of
 646 *Wolbachia*-infected mosquito deployments in reducing the incidence of dengue and
 647 other *Aedes*-borne diseases in Niteroi, Brazil: A quasi-experimental study. *PLoS*
 648 *Neglected Tropical Diseases* *15*, e0009556. 10.1371/journal.pntd.0009556.


- 649 8. Liang, X., Tan, C.H., Sun, Q., Zhang, M., Wong, P.S.J., Li, M.I., Mak, K.W., Martin-Park,
650 A., Contreras-Perera, Y., Puerta-Guardo, H., et al. (2022). *Wolbachia* wAlbB remains
651 stable in *Aedes aegypti* over 15 years but exhibits genetic background-dependent
652 variation in virus blocking. *PNAS Nexus* 1, pgac203. 10.1093/pnasnexus/pgac203.
- 653 9. Nazni, W.A., Hoffmann, A.A., NoorAfizah, A., Cheong, Y.L., Mancini, M.V., Golding, N.,
654 Kamarul, G.M.R., Arif, M.A.K., Thohir, H., NurSyamimi, H., et al. (2019).
655 Establishment of *Wolbachia* strain wAlbB in Malaysian populations of *Aedes aegypti*
656 for Dengue control. *Current Biology* 29, 4241-4248 e4245.
657 10.1016/j.cub.2019.11.007.
- 658 10. Ryan, P.A., Turley, A.P., Wilson, G., Hurst, T.P., Retzki, K., Brown-Kenyon, J., Hodgson,
659 L., Kenny, N., Cook, H., Montgomery, B.L., et al. (2019). Establishment of wMel
660 *Wolbachia* in *Aedes aegypti* mosquitoes and reduction of local dengue transmission
661 in Cairns and surrounding locations in northern Queensland, Australia. *Gates Open*
662 *Research* 3, 1547. 10.12688/gatesopenres.13061.2.
- 663 11. Utarini, A., Indriani, C., Ahmad, R.A., Tantowijoyo, W., Arguni, E., Ansari, M.R.,
664 Supriyati, E., Wardana, D.S., Meitika, Y., Ernesia, I., et al. (2021). Efficacy of
665 *Wolbachia*-infected mosquito deployments for the control of dengue. *New England*
666 *Journal of Medicine* 384, 2177-2186. 10.1056/NEJMoa2030243.
- 667 12. Hien, N.T., Anh, D.D., Le, N.H., Yen, N.T., Phong, T.V., Nam, V.S., Duong, T.N.,
668 Nguyen, N.B., Huong, D.T.T., Hung, L.Q., et al. (2021). Environmental factors
669 influence the local establishment of *Wolbachia* in *Aedes aegypti* mosquitoes in two
670 small communities in central Vietnam. *Gates Open Research* 5, 147.
671 10.12688/gatesopenres.13347.2.
- 672 13. Ross, P.A., Elfekih, S., Collier, S., Klein, M.J., Lee, S.S., Dunn, M., Jackson, S., Zhang, Y.,
673 Axford, J.K., Gu, X., et al. (2023). Developing *Wolbachia*-based disease interventions
674 for an extreme environment. *PLoS Pathogens* 19, e1011117.
675 10.1371/journal.ppat.1011117.
- 676 14. Sarwar, M.S., Jahan, N., Ali, A., Yousaf, H.K., and Munzoor, I. (2022). Establishment of
677 *Wolbachia* infection in *Aedes aegypti* from Pakistan via embryonic microinjection
678 and semi-field evaluation of general fitness of resultant mosquito population.
679 *Parasites and Vectors* 15, 191. 10.1186/s13071-022-05317-4.
- 680 15. Brady, O.J., Kharisma, D.D., Wilastonegoro, N.N., O'Reilly, K.M., Hendrickx, E., Bastos,
681 L.S., Yakob, L., and Shepard, D.S. (2020). The cost-effectiveness of controlling dengue
682 in Indonesia using wMel *Wolbachia* released at scale: a modelling study. *BMC*
683 *Medicine* 18, 1-12.
- 684 16. Ahmad, N.A., Mancini, M.V., Ant, T.H., Martinez, J., Kamarul, G.M.R., Nazni, W.A.,
685 Hoffmann, A.A., and Sinkins, S.P. (2021). *Wolbachia* strain wAlbB maintains high
686 density and dengue inhibition following introduction into a field population of *Aedes*
687 *aegypti*. *Philosophical Transactions of the Royal Society B* 376, 20190809.
688 10.1098/rstb.2019.0809.
- 689 17. Cheong, Y.L., Nazni, W.A., Lee, H.L., NoorAfizah, A., MohdKhairuddin, I.C., Kamarul,
690 G.M.R., Nizam, N.M.N., Arif, M.A.K., NurZatilaqmar, Z.M., Irwan, S.M., et al. (2023).
691 Spatial distribution and long-term persistence of *Wolbachia*-infected *Aedes aegypti*
692 in the Mentari Court, Malaysia. *Insects* 14, 373. 10.3390/insects14040373.
- 693 18. Turelli, M., and Barton, N.H. (2017). Deploying dengue-suppressing *Wolbachia* :
694 Robust models predict slow but effective spatial spread in *Aedes aegypti*. *Theoretical*
695 *Population Biology* 115, 45-60. 10.1016/j.tpb.2017.03.003.







- 696 19. Turelli, M., and Barton, N.H. (2022). Why did the *Wolbachia* transinfection cross the
697 road? Drift, deterministic dynamics, and disease control. *Evolution Letters* 6, 92-105.
- 698 20. Gesto, J.S.M., Ribeiro, G.S., Rocha, M.N., Dias, F.B.S., Peixoto, J., Carvalho, F.D.,
699 Pereira, T.N., and Moreira, L.A. (2021). Reduced competence to arboviruses
700 following the sustainable invasion of *Wolbachia* into native *Aedes aegypti* from
701 Southeastern Brazil. *Scientific Reports* 11, 10039. 10.1038/s41598-021-89409-8.
- 702 21. Ross, P.A., Ritchie, S.A., Axford, J.K., and Hoffmann, A.A. (2019). Loss of cytoplasmic
703 incompatibility in *Wolbachia*-infected *Aedes aegypti* under field conditions. *PLoS*
704 *Neglected Tropical Diseases* 13, e0007357. 10.1371/journal.pntd.0007357.
- 705 22. Garcia, G.D., Sylvestre, G., Aguiar, R., da Costa, G.B., Martins, A.J., Lima, J.B.P.,
706 Petersen, M.T., Lourenço-de-Oliveira, R., Shadbolt, M.F., Rasic, G., et al. (2019).
707 Matching the genetics of released and local *Aedes aegypti* populations is critical to
708 assure *Wolbachia* invasion. *Plos Neglected Tropical Diseases* 13, e0007023.
709 10.1371/journal.pntd.0007023.
- 710 23. Hancock, P.A., White, V.L., Ritchie, S.A., Hoffmann, A.A., and Godfray, H.C. (2016).
711 Predicting *Wolbachia* invasion dynamics in *Aedes aegypti* populations using models
712 of density-dependent demographic traits. *BMC Biology* 14, 96. 10.1186/s12915-016-
713 0319-5.
- 714 24. Yeap, H.L., Rasic, G., Endersby-Harshman, N.M., Lee, S.F., Arguni, E., Le Nguyen, H.,
715 and Hoffmann, A.A. (2016). Mitochondrial DNA variants help monitor the dynamics
716 of *Wolbachia* invasion into host populations. *Heredity* 116, 265-276.
717 10.1038/hdy.2015.97.
- 718 25. Valdez-Delgado, K.M., Moo-Llanes, D.A., Danis-Lozano, R., Cisneros-Vazquez, L.A.,
719 Flores-Suarez, A.E., Ponce-Garcia, G., Medina-De la Garza, C.E., Diaz-Gonzalez, E.E.,
720 and Fernandez-Salas, I. (2021). Field effectiveness of drones to identify potential
721 *Aedes aegypti* breeding sites in household environments from Tapachula, a dengue-
722 endemic city in Southern Mexico. *Insects* 12, 663. 10.3390/insects12080663.
- 723 26. Ross, P.A., Wiwatanaratnabutr, I., Axford, J.K., White, V.L., Endersby-Harshman,
724 N.M., and Hoffmann, A.A. (2017). *Wolbachia* infections in *Aedes aegypti* differ
725 markedly in their response to cyclical heat stress. *Plos Pathogens* 13, e1006006.
726 10.1371/journal.ppat.1006006.
- 727 27. Mancini, M.V., Ant, T.H., Herd, C.S., Martinez, J., Murdochy, S.M., Gingell, D.D.,
728 Mararo, E., Johnson, P.C.D., and Sinkins, S.P. (2021). High temperature cycles result
729 in maternal transmission and Dengue infection differences between *Wolbachia*
730 strains in *Aedes aegypti*. *mBio* 12, e0025021. 10.1128/mBio.00250-21.
- 731 28. Jasper, M., Schmidt, T.L., Ahmad, N.W., Sinkins, S.P., and Hoffmann, A.A. (2019). A
732 genomic approach to inferring kinship reveals limited intergenerational dispersal in
733 the yellow fever mosquito. *Molecular Ecology Resources* 19, 1254-1264.
734 10.1111/1755-0998.13043.


735

736

737







- Dengue data collated from 20 high rise residential areas with *Wolbachia* releases
- Comparisons with controls indicate a reduction of 62.4% in dengue fever incidence
- Dengue reduction increased with *Wolbachia* frequency to a predicted 75.8% at 100%

Journal Pre-proof

KEY RESOURCES TABLE

REAGENT OR RESOURCE	SOURCE	IDENTIFIER
Biological samples		
wAlbB carrying <i>Aedes aegypti</i>	Microinjected line from Ant et al. ⁴ and field sourced infected mosquitoes from areas where line established ⁹	N/A
Deposited data		
Data generated during the study	This study	https://doi.org/10.26188/24314689.v1
Software and algorithms		
Analysis code	Similar to Nazni et al. ⁹	https://github.com/goldingn/wolbachia_kl
Vegan package	N/A	https://cran.r-project.org/web/packages/vegan/vegan.pdf
greta	N/A	https://github.com/greta-dev/greta
coda	N/A	https://rdrr.io/cran/coda/